TCM 800B
Latest Information Update: 30 Aug 2023
At a glance
- Originator TCM Biotech International
- Developer Industrial Technology Research Institute; TCM Biotech International
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 30 Aug 2023 NDR #29: Development has been discontinued as there is no development from 4 years and drug is no longer visible on the company pipeline. Introduction updated. Dev line forwarded from NDR to discontinued, HE added. Introduction updated.
- 30 Aug 2023 Discontinued - Preclinical for Hepatitis B in Taiwan (unspecified route) (TCM Biotech pipeline, August 2023)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Hepatitis-B in Taiwan